Actionable news
0
All posts from Actionable news
Actionable news in VRX: VALEANT PHARMACEUTICALS INTERNATIONAL,

15 Stocks Moving In Wednesday's Pre-Market Session


Gainers

  • Progenics Pharmaceuticals, Inc. PGNX rose 22.1 percent to $6.03 in pre-market trading after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
  • Towerstream Corporation TWER shares rose 17.1 percent to $3.76 in pre-market trading after surging 29.44 percent on Tuesday. Towerstream is scheduled to report Q2 financial results on August 9, 2016.
  • TerraForm Global Inc GLBL shares rose 15.4 percent to $3.75 in pre-market trading. TerraForm Global reported preliminary unaudited financial information for the second half of 2015 and first quarter of 2016. Terraform Global Inc reported that SunEdison Inc is planning to sell its interest in the Terraform.
  • Intuitive Surgical, Inc. ISRG rose 6.7 percent to $717.14 in pre-market trading after the company posted stronger-than-expected results for the second quarter on Tuesday.
  • Microsoft Corporation MSFT shares rose 5.1 percent to $55.78 in pre-market trading after the company reported better-than-expected fiscal fourth-quarter financial results on Tuesday.
  • Valeant Pharmaceuticals Intl Inc VRX rose 4.5 percent to $24.60 in pre-market trading as the company reported that the FDA has approved RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
  • Morgan Stanley MS rose 3.2 percent to $29.09 in the pre-market trading session after the bank announced better-than-expected adjusted earnings and revenue for the second quarter.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

  • Zafgen Inc ZFGN shares fell 43.7 percent to $3.80 in the pre-market trading session after the company reported that it has suspended the development of its obesity drug Beloranib.

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.